YZYujing Zou

Yujing Zou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yujing Zou has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic data extraction harnessing a privacy-preserving large language model: a clinician-AI collaborative retrospective evaluation in head and neck oncology

    by Yujing Zou, Laya Rafiee Sevyeri, Farhood Farahnak, George Shenouda, Marie Duclos, Tomás Yokoo Teodoro de Souza, Khalil Sultanem, Parsa Bagherzadeh, Farhad Maleki, Shirin A. Enger

    Privacy regulations and limited expert-validation constrain the deployment of large language models (LLMs) for electronic health record structuring. We evaluated locally deployed LLMs to extract 30 prognostic variables from 1,360 head and neck cancer reports (882 patients) using zero-shot prompting. A stratified 50-case subset was reviewed by three radiation oncologists (50 cases, 30 fields, 3 reviewers; 4,500 decisions) to form a majority-vote reference for Llama3.3-70B, which achieved 98.6% F1 with high clinician agreement and processed reports in 53 s/report. Among seven additional models (2.6B-70B) benchmarked against this reference, GPT-OSS-20.9B (F1 89.4%) and MedGemma-27B (F1 88.5%) performed best. Integrating LLM-extracted HPV status, smoking history, and Charlson Comorbidity Score into a multivariate Cox Proportional Hazards model (age, sex, T/N stage) improved disease-free survival (likelihood ratio test p = 0.014; ΔC-index + 0.071) and locoregional failure-free survival (p = 0.026; ΔC-index + 0.108) with 1,000-bootstrap internal validation. This clinician-AI collaborative evaluation shows that on-premises LLMs enable privacy-preserving and efficient tumour board support, longitudinal data curation, and outcome prediction.

  • Open Access

    Trends in brachytherapy utilization in Canada from 2011 to 2020

    by Mirta Dumančić, Yujing Zou, Harry Glickman, Sara Ghassimi Kouraneh, Piotr Pater, Andrew Alexander, Jorge E. Alpuche Aviles, Amanda Cherpak, Kristin Marchant, Geetha Menon, et al.

  • Open Access

    Tumour nuclear size heterogeneity as a biomarker for post-radiotherapy outcomes in gynecological malignancies

    by Yujing Zou, Harry Glickman, Manuela Pelmus, Farhad Maleki, Boris Bahoric, Magali Lecavalier-Barsoum, Shirin A. Enger


  • Generative Style Transfer for MR Image Segmentation: A Case of Glioma Segmentation in Sub-Saharan Africa

    by Rancy Chepchirchir, Jill Sunday, Raymond Confidence, Dong Zhang, Talha Chaudhry, Udunna C. Anazodo, Kendi Muchungi, Yujing Zou


  • Open Access

    Generative Style Transfer for MRI Image Segmentation: A Case of Glioma Segmentation in Sub-Saharan Africa

    by Rancy Chepchirchir, Jill Sunday, Raymond Confidence, Dong Zhang, Talha Chaudhry, Udunna C. Anazodo, Kendi Muchungi, Yujing Zou

    In Sub-Saharan Africa (SSA), the utilization of lower-quality Magnetic Resonance Imaging (MRI) technology raises questions about the applicability of machine learning methods for clinical tasks. This study aims to provide a robust deep learning-based brain tumor segmentation (BraTS) method tailored for the SSA population using a threefold approach. Firstly, the impact of domain shift from the SSA training data on model efficacy was examined, revealing no significant effect. Secondly, a comparative analysis of 3D and 2D full-resolution models using the nnU-Net framework indicates similar performance of both the models trained for 300 epochs achieving a five-fold cross-validation score of 0.93. Lastly, addressing the performance gap observed in SSA validation as opposed to the relatively larger BraTS glioma (GLI) validation set, two strategies are proposed: fine-tuning SSA cases using the GLI+SSA best-pretrained 2D fullres model at 300 epochs, and introducing a novel neural style transfer-based data augmentation technique for the SSA cases. This investigation underscores the potential of enhancing brain tumor prediction within SSA's unique healthcare landscape.


  • Open Access

    NK cell predicts the severity of acute graft-versus-host disease in patients after allogeneic stem cell transplantation using antithymocyte globulin (ATG) in pretreatment scheme

    by Ping Zhang, Shujun Yang, Yujing Zou, Xiao Yan, Hao Wu, Miao Zhou, Yong Cheng Sun, Yi Zhang, Huiling Zhu, Kaihong Xu, et al.

    Background: Graft-versus-host disease (GVHD) is one of the most complex complications after allogeneic stem cell transplantation. Current standard of grading system is based on clinical symptoms in skin, liver and intestinal. However, it’s difficult to differ GVHD and its extent just by clinical manifestation. Here we retrospectively analyzed cell immune function in patients implemented allogeneic stem cell transplantation in Ningbo first Hospital from Jan 2013 to Jan 2018. Results: the data are collected from 51 patients (mean age was 42; 45.1% women). The average NK cell percentage was 39.31% in severe GVHD (Grade III-IV), was 16.98% in mild GVHD (GradeI-II), while was 21.15% in No GVHD group. The statistical analysis showed difference among each grade. Further analysis was performed in Antithymocyte globulin (ATG) treated group and control group. We showed NK Cell percentage was sharply different in ATG treated group: 47.34% in severe GVHD, 11.98% in mild GVHD group, while 18.3% in no GVHD group. However, in control group, the average percentage of NK cells was 23.27% in severe GVHD, was 23.22%in mild GVHD group, while was 21.13% in no GVHD group. Conclusion: The data supports that ATG can prevent GVHD by increasing NK cell percentage. The percentage of NK cell seemed to be a useful probe to evaluate the severity of GVHD in allogeneic stem cell transplantation patients using ATG in pretreatment.


  • Open Access

    Microrna-191 Regulates T-Cell Clonal Expansion during Graft-Versus-Host Disease

    by Chuanfeng Xiong, Wei Huang, Xiaoli Nie, Ying Huang, Yiqun Jiao, Yujing Zou, Charles Huang, Emilio Feijoo, Dong Pan, Diana M Cardona, et al.

    Allogeneic hematopoietic cell transplantation is a potentially curative treatment choice for a wide variety of hematological malignancies. However, graft-versus-host disease (GVHD), which is mediated by donor alloreactive T cells, limits the success of this procedure. Previous studies have demonstrated that several microRNAs (miRs) modulate graft-versus-host disease. miR-191 was previously reported to be able to support T cell survival after TCR stimulation. We hypothesize that miR191 regulates T cell response during GVHD. To test this hypothesis, we first studied miR-191 expression in alloreactive T cells. The result demonstrated that miR-191 was up-regulated in donor T cells isolated from murine GVHD recipients, suggesting that miR-191 may play a role in GVHD induction. We further studied the role of miR-191in GVHD using miR-191 deficient T cells (KO). Lethally irradiated (8.5 Gy) BALB/c mice were injected intravenously with 1×107 T cell-depleted bone marrow (TCDBM) cells along with 1×106 purified T cells from wild-type (WT) or KO mice, which are in C57BL/6 background. Interestingly, all recipients in the WT group died within 35 days after transplantation, while only one out of ten animals died in the KO group during an observation period of 56 days. Body weights and clinical scores were also improved in KO T cell recipients when compared with the WT controls. Similar results were also observed in a second GVHD model (C57BL/6→C3H/HeJ). To understand the mechanism by which miR-191 KO T cells have decreased ability to mediate GVHD, we first measured the ability of KO T cells to respond to alloantigens in vitro in a mixed lymphocytes reaction assay. Dramatically decreased alloresponse was observed with KO T cells as compared with WT T cells. Similarly, decreased clonal expansion was observed in KO T cells in vivo upon challenge with alloantigens as measured by bioluminescent imaging (Figure 1A). These results were further supported by data from a co-transfer experiment, in which equal numbers of WT and KO T cells were transplanted into the same GVHD recipient. At day7 after transplantation, KO T cells showed significantly reduced expansion in the spleen and liver compared with WT T cells. Reduced alloresponses mediated by KO T cells may not due to decreased proliferative capability directly as an in vivo carboxyfluorescein succinimidyl ester (CFSE) assay showed a comparable cell division between WT and KO T cells upon challenge with alloantigens. Rather, increased cell death is responsible for decreased alloresponse observed in KO T cells because dramatically increased number of dead cells was observed in KO group compared with WT group upon response to alloantigens in vitro and vivo. To determine the genes that are regulated by miR-191, we did a screening based on the prediction. Humans and mice share more than 100 predicted targets for miR-191. We chose top 20 of these targets for RT-qPCR screening. The result demonstrated that Taf5 was a target gene of miR-191. Expression of TAF5 protein was down-regulated in activated KO T cells when compared with the WT T cells. Finally, we investigated whether miR-191 KO T cells preserve graft-versus-leukemia effects. 1×106 T cells from WT or KO mice were transplanted into lethally irradiated BALB/c mice along with 1×107 TCDBM cells and 1×105 host-type BCL-1 cells. While all recipients that received only TCDBM and tumor cells developed lethal leukemia/lymphoma, none of WT and KO T cells recipients developed tumor. In conclusion, our findings reveal a critical role of miR-191 during GVHD process and demonstrate that miR-191 is a novel therapeutic target for GVHD.